Now showing items 1-1 of 1

    • Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML 

      Basheer, F; Giotopoulos, G; Meduri, E; Yun, H; Mazan, M; Sasca, D; Gallipoli, P; Marando, L; Gozdecka, M; Asby, R (Rockefeller University Press, 2019-03-19)
      Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the ...